AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China

HONG KONG, Aug 10, 2021 – (ACN Newswire) – China Biotech Services Holdings Limited ("CH BIOTECH SER " or "Company", stock code: 8037.HK) is pleased to announce that Asia Molecular Diagnostic Laboratory ("AMDL"), a subsidiary of the Company, has been exclusively licensed by its shareholder Pillar Biosciences, Inc. ("Pillar") to distribute Pillar's FDA (U.S. Food and Drug Administration) approved oncoRevealTM Dx Lung and Colon Cancer Assay (the "Assay") in part of Asian countries including China (specifically in Guizhou, Sichuan, Liaoning, Hong Kong and Macau), all ASEAN countries & etc. (collectively, the "Regions").

Pillar, an invested enterprise of CH BIOTECH SER, received the Premarket Approval ("PMA") on its oncoReveal(TM) Dx Lung and Colon Cancer Assay from FDA on July 30th, 2021. CH BIOTECH SER currently holds a seat on the board of Pillar.

The Assay is a NGS tissue-based companion diagnostic test for qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The grant of oncoReveal(TM) Dx Lung and Colon Cancer Assay's PMA was based on clinically validated data and allows for the test to be used as a companion diagnostic test for all FDA-approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapies for NSCLC targeting EGFR mutations (Exon 19 In Frame Deletions and Exon 21 L858R Substitution Mutations), and KRAS wild-type tumor tissue (absence of mutations in codons 12 and 13) for metastatic colorectal cancer patients. It can provide guidance to clinicians when it is necessary to use Erbitux (cetuximab) or Vectibix (panitumumab) for Targeted Therapy. This test is suitable for Illumina MiSeqTM Dx sequencer, which is Illumina's NGS platform for In Vitro Diagnostic (IVD) testing.

NGS is characterized by high throughput, a large amount of sequence data can be obtained at the same time, and the sequencing cost is low when compared to the traditional sequencing method. Since NGS can detect many unknown mutations, this technology has stronger predictive power than PCR-based detection technology. Therefore, the market generally believes that NGS detection technology can replace PCR-based technology in the future and become the mainstream of the market. However, in the current market, whether it is the United States or China, the proportion of approved NGS companion diagnostic products is still small. Take the Chinese market as an example, NGS products began to be approved in 2018, and as of December 2020, there are only 9 NGS products approved in China.

On Jan 10th, 2019, CH BIOTECH SER and Pillar entered into a strategic partnership. Under the terms of their strategic agreement, CH BIOTECH SER and Pillar formed a joint venture, AMDL. AMDL holds the exclusive right to market all the products of Pillar in the Regions. AMDL has set up a clinical molecular diagnostic laboratory in Hong Kong Science & Technology Park. It is dedicated to developing and providing affordable high quality precision diagnostic products and services to the Regions. In the future, Pillar is expected to launch more NGS products for testing other cancers, which will bring more business growth points to CH BIOTECH SER, which has the Pillar's product distribution right. From this perspective, the strategic cooperation between CH BIOTECH SER and Pillar can undoubtedly generate huge synergies, creating new growth points for the company's deployment of accurate diagnostic services in the Asian region, and its intrinsic value will continue to grow with the approval of Pillar's new products.

About Pillar Biosciences, Inc.
Pillar is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. It is dedicated to enabling global access to high quality, affordable, and specialty NGS testing. Colombia University, Dana Farber Cancer Institute of Harvard University, Massachusetts General Hospital and Yale University are among Pillar's major clients.

About China Biotech Services Holdings Limited
China Biotech Services Holdings Limited (CH BIOTECH SER) was included in the MSCI Hong Kong Micro Cap Index in May 2018. The main business is the standard pathology laboratory, which is one of the largest third-party medical testing center in Hong Kong. It has been rooted in Hong Kong for 50 years. And for the development of precision diagnosis and cell therapy, it is engaged in cell drug development, medical detection and cancer precision detection and other businesses, and builds an advanced biotechnology platform. There are currently more than 10 CAR-T products under development; four of them have international technology patents; six of them are in patent application. The indications cover B-cell lymphoma and leukemia, as well as several solid tumors with great market potential. During the outbreak of the coronavirus, the Sunrise Diagnostic Centre Limited, a joint venture registered by China Biotech Services and BGI Hong Kong, provided Hong Kong citizens with new coronavirus testing, with remarkable results.

For more information on China Biotech Services Holdings Limited, please visit the company website http://www.cbshhk.com/index.htm/.

This press release is issued by the Porda Havas International Financial Communications Group on behalf of China Biotech Services Holdings Limited.

Porda Havas International Finance Communications Group
Ms. Kelly Fung +852 3150 6763 kelly.fung@pordahavas.com
Ms. Stephanie Yao +852 3150 6737 stephanie.yao@pordahavas.com
Ms. Alyssa Yiu +852 3150 6781 alyssa.yiu@pordahavas.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership

ADELAIDE, AUS, Aug 10, 2021 – (ACN Newswire) – Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.

Avance Clinical is an Australian owned Contract Research Organisation (CRO) that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 24 years.

Frost & Sullivan says the Asia-Pacific's CRO market value, currently at $6.01 billion, is estimated to reach nearly $11.04 billion in 2026, growing at a compound annual rate of 12.2%.

"The region is becoming the go-to research and development market, with China, Japan, Australia, and South Korea in the lead, accounting for 16% of the APAC clinical CRO market in 2020," according to Supriya Lala Kundu, Best Practices Research Analyst, Frost & Sullivan.

This is the second Frost & Sullivan award for Avance Clinical, which has seen rapid growth in the APAC region over the past year.

Avance Clinical's CEO Yvonne Lungershausen commended her team of more than 150 clinical trial specialists across Australia and New Zealand.

"We have shown, with our 89% growth and repeat business rate of greater than 70% that our focus on gold standard technology paired with solution-orientated clinical experts is the mix clients require in this fast moving, competitive and high-stakes sector. Avance Clinical is immensely proud of this acknowledgment. This award is real recognition of our successful approach to delivering value to our customers.

Clients talk about the advantage of Australia's financial tax rebate incentive of almost 50% on clinical trial spend – but I believe the real benefit is in saving time. Our biotech clients can leverage fast start up with the Australian regulatory process and obtain early clinical data without first acquiring their in-country IND. The net effect for our clients is they can speed up their clinical program by getting into the clinic up to a year earlier than anywhere else in the world, and saving significant associated costs."

Avance Clinical specialises in supporting biotech companies with their early phase clinical trials having conducted over 195 early phase (Phase 1 and 2) trials in the past 5 years involving over 10,000 participants across 105 therapeutic indications.

According to Supriya Lala Kundu, Best Practices Research Analyst, Frost & Sullivan:

"Avance Clinical has grown rapidly over the past year since our last analyst review, including further expansions of clinical services across Australia and New Zealand. Its impressive repeat business rate of greater than 70% speaks to its customer value and reputation in the sector and is a key factor in the 2021 award selection.

Avance Clinical's clients are international biotech companies primarily from the United States, United Kingdom, Japan, China, South Korea, Taiwan, France, and Germany. These clients are seeking a premium CRO with the same experience and advanced technology platforms offered by the major global CROs, but with an agile and customer focused approach to clinical management in Australia and New Zealand.

The company offers best-in-class technologies from leaders such as Oracle, Medidata and Medrio, enabling rapid high-quality data management accepted by all the major regulatory authorities globally, with a highly experienced team of more than 150 clinical specialists, with deep experience across more than 105 indications.

The company's accreditation as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) has allowed it to expand into clinical trials for vaccines and GMO therapies.

Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials."

Key Frost & Sullivan analyst findings around the Avance Clinical offering include:

– Financial Performance: Strong overall financial performance is achieved in terms of revenues, revenue growth, operating margin, and other key financial metrics
– Customer Acquisition: Customer-facing processes support efficient and consistent new customer acquisition while enhancing customer retention
– Operational Efficiency: Company staff performs assigned tasks productively, quickly, and to a high-quality standard
– Growth Potential: Growth is fostered by a strong customer focus that strengthens the brand and reinforces customer loyalty
– Human Capital: Commitment to quality and to customers characterize the company culture, which in turn enhances employee morale and retention
– Price/Performance Value: Products or services provide the best value for the price compared to similar market offerings
– Customer Purchase Experience: Quality of the purchase experience assures customers that they are buying the optimal solution for addressing their unique needs and constraints
– Customer Ownership Experience: Customers proudly own the company's product or service and have a positive experience throughout the life of the product or service
– Customer Service Experience: Customer service is accessible, fast, stress-free, and high quality
– Brand Equity: Customers perceive the brand positively and exhibit high brand loyalty

Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/
For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About Avance Clinical www.avancecro.com

Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs for 24 years. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan awards
Avance Clinical is a Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award recipient and a 2021 Asia-Pacific CRO Customer Value Leadership Award recipient.

Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

Avance Clinical delivers customised solutions designed around specific client needs rather than a one size fits all approach. With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
As a company, Avance Clinical has focused on state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.

Media Contact:
Chris Thompson
media@avancecro.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

TIENS Group Initiates Post-Pandemic Forum on Global Health

TIANJIN, China, Aug 6, 2021 – (ACN Newswire) – TIENS Group has hosted "One Belt One Road: Health Industry Development Forum for the Post-Pandemic Era" on August 3, 2021. The forum acted as a platform for industry leaders and stakeholders from different sectors to meet up and delve into health industry challenges, addressing them in turn for the post-pandemic era.

Later, the guests debated innovation, reform and improvement in the global health industry. China, which has become a stern yet exemplary leader in the world's post-pandemic era, is leading the movement of change in the health industry. Global health sectors, especially in Asia, have benefited greatly from China's supply chain model and the innovation brought about by the Belt and Road Initiative.

TIENS Group plays a representative role in China's health care industry, a major reason for its steady growth. Li Jinyuan, Chairman of TIENS Group, delivered the hallmark mentioning design and efficiency in the health industry today and spoke of his Group's endeavours and the support they have received from Chinese Belt and Road policy. A strong advocate of the Belt and Road Initiative, TIENS Group makes no secret of this progress helping them.

The global progress of Chinese enterprises means keeping abreast of the times. TIENS Group enjoys an excellent reputation in today's market and proudly carries the "Made in China" label on all its great health products. Currently, its business has expanded to Europe, Asia, Germany, Russia, Africa, and other regions around the globe. The Group has its own logistics in many countries as it covers the world through its own expanding operations.

TIENS Group has been engaged in the larger health industry for 26 years. It has accumulated profound experience in the domestic and foreign markets, setting up solid supply channels, accumulating growing numbers of customers, and building a well-known brand. As a result, it holds the balance in the health industry both at home and abroad.

The TIENS Group aims to strengthen its exchange and cooperation with domestic and foreign enterprises over this broad platform, jointly promoting the development of the health industry with others, and making a greater contribution to the health of the world's citizenry. Please visit the company's website at https://www.tiens.com/.

Media contact:
Yukai Wang, TIENS Group
E: zcfw@tiens.com
U: https://www.tiens.com/

SOURCE: TIENS Group

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Following Series A Financing, Scivita Medical Completes Series B Financing of Nearly RMB0.4 Billion to Accelerate the Strategic Layout of Globalization

HONG KONG, Aug 5, 2021 – (ACN Newswire) – Following the completion of series A round financing, with the acceleration of the research and development and commercialization of endoscopy product, Scivita Medical Technology Co., Ltd. ("Scivita Medical") announced today that it has received nearly RMB0.4 Billion in Series B financing, with new investors such as Hudson Bay Capital Management and Prime Capital, as well as continuous support from existing shareholders such as GL Ventures, Lilly Asia Ventures and Matrix Partners China. This round of financing will continue to be used for research and development, capacity expansion, and domestic and international commercialization of innovative products in endoscopy and related fields.

Since its inception, Scivita Medical has taken globalization as an important strategy and has set up R&D centers in Suzhou, China and Tokyo, Japan to promote simultaneous global R&D, patent application, registration and commercialization of its products, and strives to building a global leading platform for innovative products in endoscopy and related fields. The successful completion of this round of financing fully reflects the recognition of the new investors and the existing shareholders for the future development potential and the expectation of the sustainable development of Scivita Medical.

Driven by factors such as the promotion of graded treatment, the development of minimally invasive surgery and the aging population, the market demand and configuration rate of endoscopes are rising rapidly. Scivita Medical has a comprehensive product line covering both rigid and flexible endoscopes, reusable endoscopes, single-use endoscopes, white light endoscopes, fluorescent endoscopes, etc. Currently, Scivita Medical's commercialized products include3D Visualization System, 4K UHD Camera System, 4K-3D Camera System, 4K Sinoscope, 4K Arthroscope, Single-use Hystero Videoscope, Single-use Urology Videoscope, Single-use Broncho Videoscope, etc. In the future, Scivita Medical will continue to launch new products while promoting the simultaneous certification of related products in China, the United States, Japan, Europe and other countries and regions, and continue to promote the products to the global market.

Scivita Medical's innovation has been ahead of the market with industry leading position, which reflects Scivita Medical's R&D strength and confidence. Scivita Medical has global cutting-edge technologies, including ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology(including monocular 3D and binocular 3D), single-use technology, special light visualization technology (such as fluorescence visualization), and ultra-fine endoscopic technology. In the future, Scivita Medical will also integrate the existing technologies to form a diversified product matrix such as 4K fluorescence and 3D fluorescence.

Scivita Medical aims at solving clinical pain points through technological innovation and developing high quality products that suit the needs of clinicians. For example, in the development process of4K UHD visualization, through cooperation between medical staff and the industry, Scivita Medical learned the pain points in laparoscopy such as "endoscope fogging" or "smoke interference", and successfully developed the lens tip heating feature, effectively avoiding fogging caused by temperature differences. The signal processing technology enables the one-key fogging removal function on the camera, which effectively removes smoke interference and improve the efficiency of surgery. In addition to effectively solving the problem of cross-contamination, the single-use endoscopes independently developed by Scivita Medical also enables the image quality to reach the standard of reusable endoscope. In addition, Scivita Medical has fully considered the ergonomics in product development process, and its single-use endoscopes not only allow clinicians to control flexibly with both left and right hands, but also meet the needs of clinicians in different scenarios of standing or sitting diagnosis, effectively alleviating clinicians' operational fatigue and improving diagnosis and treatment efficiency for the benefit of more patients.

In terms of imaging clarity, color reproduction, or operability, conductivity, and insertion of endoscope, the clinical evaluation of Scivita Medical's products have reached the international first-class level. In the past few years, most of the terminal hospitals where Scivita Medical's products are sold in China are the tertiary hospitals represented by domestic tertiary Grade A hospitals, and the products are on par with major international brand products in terms of product quality and effect. In the future, in addition to insisting on the strategic goal of making high-end Made-in-China products, Scivita Medical will also launch generic endoscope systems for hospitals at all levels, and benefit hospitals at all levels with products of international leading level.

In the future, Scivita Medical will continue to implement the strategy of globalization, deepen its focus on clinical needs and pain points, and work together with global clinical experts to promote the development of the endoscopy industry and enhance the level of safety, effectiveness and accuracy of treatments, thereby benefiting patients around the world.

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

From Red Gold to Olympic Gold: Seedo Corp. Seeks Solutions for Athletes and More

Tel Aviv, Israel, Aug 4, 2021 – (ACN Newswire) – Seedo Corp. (http://saffron-tech.ag) (OTC: SEDO), an agtech company that is developing the protocols to grow saffron using vertical farming technology, today announced that it is expanding its research to include the study of the spice's well known natural anti-anxiety and antidepressant properties. Similar to the approach of the indoor cannabis industry, Seedo hopes to be able to enhance the medicinal properties of this unique herb for use in pharmaceutical and nutraceutical applications. Mental health has come to the forefront in sports with Simone Biles withdrawing from the Tokyo Olympics and Naomi Osaka opting out of the French Open and Wimbledon. With mental health entering the cultural conversation, Seedo Corp. hopes saffron will be seen as part of a new nature-based approach to mental health.

Simone Biles

"The timing is right to leverage saffron's potential medicinal properties and create new applications that could address the recent paradigm shift regarding mental health," says David Freidenberg, CEO. "Seedo Corp is committed to developing breakthroughs rooted in nature that are effective and safe for athletes and everyday consumers alike."

"Until recently, the options for treating depression and anxiety were quite limited," says Dr. Nizan Primor, CEO, Naveh Pharma, a company that specializes in creating pharmaceutical and healthcare products with unique active ingredients including saffron. "A recent study (https://pubmed.ncbi.nlm.nih.gov/31118846/) found that taking 28 mg of saffron daily was just as effective as Fluoxetine, Imipramine, and Citalopram — conventional treatments for depression."

A fascinating study was published in the Journal of Adolescent Psychopharmacology (https://pubmed.ncbi.nlm.nih.gov/30741567/) which explicitly found that saffron extract has the same efficacy as Ritalin in improving focus for children with ADHD, suggesting there is a promising future in developing new natural therapies to treat these common ailments. In another recent study by the Journal of Psychopharmacology (https://journals.sagepub.com/doi/abs/10.1177/0269881119867703) it was discovered that patients who were administered saffron extract for eight weeks saw "a greater improvement in depressive symptoms."

Seedo Corp successfully harvests saffron using vertical farming technology. Seedo Corp hopes to expand the billion dollar saffron market by producing a reliable, consistent and large-scale supply of the spice.

About Seedo

Seedo Corp. (OTC: SEDO) is an agtech company that focuses on the research, development, and commercialization of agriculture products that are high in demand but are hindered by the low yields and specifications required by traditional farming. Seedo's technology is aimed at offering a responsible and sustainable way to grow crops in a world confronted by environmental challenges and dwindling earth reserves, diminishing water sources and unstable weather conditions.

Cautionary Note Regarding Forward-Looking Statements

This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our ability to successfully execute a smooth transition of CFO functions as well as our ability to retain and recruit qualified executives; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; our ability to successfully compete in the marketplace; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Reports on Form 10-Q and in our Annual Report on Form 10-K, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Contact:
David Freidenberg,
Chief Executive Officer
info@saffron.ag
+1 (800) 608-6432

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

ClinTex (CTi) Launches CTi-OEM Blockchain Clinical Trial App

LONDON, Aug 3, 2021 – (ACN Newswire) – The ClinTex (CTi) tokenized platform (clintex.io) will be the first of its kind to utilize blockchain-based clinical data analytics to address the main causes of clinical trial inefficiency, helping to drive down the cost of new medicines and expediting their delivery to patients.

ClinTex launches 'Operational Excellence' – a blockchain clinical trial application to tackle clinical trial inefficiencies and high costs.

The initial spark of an idea that would eventually become ClinTex started in 2014, at the DIA Forum in Vienna. By 2018, Clintex was formally working on the Clinical Trials Intelligence (CTi) platform. CTi's purpose is to deliver data analysis at scale, to drive collaboration and insights across clinical trials.

With large pharma companies like Merck and Novartis already testing blockchain as a technology of the future to support their clinical trial strategy for patient information and to manage clinical trial medication, this paves the way for ClinTex CTi to partner with the industry to deliver more innovative and impactful uses of blockchain to increase clinical trial efficiency.

The CTi-OEM App

Leveraging 50+ years of medicine development experience, ClinTex has moved at a breakneck pace to launch its first blockchain clinical trial app of the CTi Platform, the Operational Excellence Module (CTi-OEM). CTi-OEM provides intuitive operational oversight of clinical trials for clinical project managers, clinical data managers and remote staff; allowing in-stream decision-making on what actions are required to ensure a successful investigation into the safety and efficacy of new medicines.

Using the CTi-OEM console, researchers can deep dive into clinical trial data and take proactive action to make clinical trials run more efficiently. These operational issues include things like clinical protocol deviations and adverse events relating to patient safety in the clinical trial.

The company has prioritized the development of the CTi-OEM blockchain clinical trial app to target some of the major causes of inefficiency in clinical trials, enabling its first app to derive maximum tangible benefits for the pharma and clinical trials industry. CTi-OEM achieves this through a comprehensive portfolio of tools, which is accessible through the CTi-OEM console.

Compliance Requirements

One of the major obstacles to a successful clinical trial is adherence to the clinical trial protocol. Analytics within the CTi-OEM application allows the detection and analysis of these deviations and allows the clinical trial team to take speedy action. These tools provide powerful insights into the major causes of non-compliance in clinical trials providing analytics to help clinical trial teams identify and resolve them to speed up progress.

Protecting patient safety during a clinical trial is the most important aspect in the development of any new medicine. Adverse events are safety issues that occur during the testing of a new medicine. CTi-OEM provides valuable insight into patient safety throughout a clinical trial. For example, adverse event rate per site allows the clinical trial team to identify those sites that have a high rate of safety events which may point to procedural problems or may also uncover safety risks that need further investigation.

These are just a few examples of CTi-OEM's toolkit. For more information on CTi-OEM, there is a series of demonstration videos that give an overview of the platform, and how it can help alleviate pain points in clinical trials.

The First App of Many

CTi-OEM is just the beginning of Clintex's offerings. Eventually, it will consist of 7 different blockchain clinical trial applications that derive intelligent analytics from all types of clinical trial data, and it is these analytics that can be used to drive efficiency in clinical trials. The ClinTex roadmap is on track to have live client onboarding and revenue generation by the end of 2022.

Any clinical trial professionals interested in becoming early adopters can email ClinTex at industry@clintex.io or visit http://clinicaltrialsintelligence.org.

ClinTex Socials
Twitter : https://twitter.com/ClinTexCTi
Telegram : https://t.me/ClinTexCTi
Medium : https://medium.com/clintexcti
YouTube : https://youtu.be/iK3zkhsDzzA
Website : https://clintex.io/

Media Contact Details
Contact Email: press@clintex.io

SOURCE: ClinTex

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Legend Capital invests in Series A funding round of BioMap, a biological computing platform

HONG KONG, Jul 30, 2021 – (ACN Newswire) – BioMap, a biological computing platform enterprise, has recently completed the Series A funding round worth over a hundred million US dollars, which Legend Capital participated in. The funds will be used to for R&D and talent recruitment.

BioMap is positioned as an innovative medicine R&D platform driven by biological computing engine. It was co-founded by Robin Li in November 2020 and he currently serves as the Chairman. Through advanced computing and biotechnology, BioMap draws maps on disease targets and drug design to realize the Global First-in-class original drugs. In the future, BioMap will also focus on the field of immune mechanism of tumors, autoimmune diseases and fibrotic diseases.

Richard Li, the President of Legend Capital, said: "It is our second cooperation with Baidu this year after the investment in Baidu's AI chip unit Kunlun in March. We hope to continue to maintain close cooperation with Baidu in the field of scientific and technological innovation in the future. We take a positive long-term view of the integration of IT and life science and technology. BioMap empowers life science with AI, and accelerates the R&D of new drugs and diagnostic products through the integration and innovation of AI technology and cutting-edge biotechnology. In the future, Legend Capital hopes to realise the full potential of the advantages of our enterprise ecosystem in the field of healthcare, and promote BioMap's cooperation with leading companies in related fields, so as to provide intelligent computing platform support for the healthcare industry, give impetus to industrial upgrading and benefit more patients. "

Legend Capital has been focusing resources to research the deep integration of healthcare industry and technology. In recent years, it has continued to explore the field of medical AI. In addition to BioMap, Legend Capital has also invested in AI microbial pharmaceutical company Xbiome, AI innovative drug development platform StoneWise, AI medical image assisted diagnosis company Deepwise, Lunit, AI medical pathology diagnosis company Deep Informatics, gene big data company Genowis, AI medical chronic disease management system company Ayshealth Technology, etc.

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine

HONG KONG, Jul 29, 2021 – (ACN Newswire) – EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limited ("Prenetics") for a strategic collaboration in relation to the formation of a "Healthnomics collaboration". The partnership will be focused on assembling health data resources from ECH and innovative genetics and diagnostic testing services from Prenetics to create the future of medicine, steering the development in preventive & precision medicine, drug discovery and health policy steering for governments.

Under the collaboration, (i) EC Healthcare shall be the designated offline fulfillment partner of Prenetics online business; (ii) EC Healthcare shall be granted the exclusive license to market and sell certain Prenetics DNA testing products under the CircleDNA and Circle Medical brand in the Greater Bay Area; (iii) EC Healthcare shall be the marketing and operational partners to promote Prenetics diagnostic and genetic testing products; and (iv) EC Healthcare and Prenetics shall jointly develop necessary IT solutions to enhance the integration of health data resources and genomics data resources.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group is delighted to establish a strategic partnership with Prenetics. Through the collaboration, we hope to divert public domain traffic into EC Healthcare's enclosed ecosystem by using Prenetics testing services and form a "Healthnomics collaboration" which will combine traditional blood-based health data and genomics risk profiling data for patients to have a holistic view on their overall health. Furthermore, the Group believes that the collaboration can promote cross-selling synergies between the Group and Prenetics, thereby creating new source of clientele and income for the Group's existing medical, aesthetic medical and wellness businesses, and enhance the loyalty of the Group's existing customers by complementing the scope of preventive and precision medical services provided."

Mr. Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics said, "We are thrilled to partner with EC Healthcare, the largest non-hospital medical group in Hong Kong. By integrating our tests to EC Healthcare's health checks and medical services, it will provide a first of its kind offering to patients which combines DNA and health data into one consolidated view. Our mission has always been about prevention, not treatment. This partnership with EC Healthcare further allows us to create new opportunities to revolutionize personalized healthcare."

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories and a professional hair care center HAIR FOREST.

*According to an independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

About Prenetics
Prenetics is a leading genetics and diagnostic health testing company, operational in 10 countries with a team of over 500, led by visionary entrepreneur, Danny Yeung. Prenetics has received over USD85-million in strategic funding from Alibaba Hong Kong Entrepreneurs Fund, Ping An Ventures, Apis Partners and more. Prenetics has to-date performed more than 4 million diagnostic and genetic tests in Hong Kong and the United Kingdom. In Hong Kong, Prenetics was the 1st private laboratory to have been appointed by the Hong Kong government for mass community Covid-19 testing. In the United Kingdom, Prenetics was instrumental in the re-start of the English Premier League season having done the testing across 20 clubs. Prenetics' mission is to decentralize healthcare and focus on the comprehensive testing capabilities covering prevention, diagnostics, and personalized care. For more information, visit https://prenetics.com.

For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Ada Chew
Tel: (852) 2136 6952 / 2169 0467 / 3920 7650
Fax: (852) 3170 6606
Email: ech@iprogilvy.com

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

EC Healthcare Announced Quarterly Sales Volume, Successfully Expanded New Flagship Service Centre

HONG KONG, Jul 27, 2021 – (ACN Newswire) – EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces that, to fulfill the strong demand for medical and healthcare services, on 26 July 2021, the Group has expanded its flagship service centre at Langham Place Office Tower in Mong Kok, with a newly leased floor with gross floor area of approximately 17,900 square feet. The newly leased floor is for the Group's businesses of aesthetic medical and medical specialist services, including but not limited to the Group's first ophthalmology centre and a new obstetrics and gynaecology centre.

After the expansion, the total service area of the Group in Langham Place Office Tower has increased to 9 floors and the aggregate floor area of the clinics and service centres of the Group increased to approximately 431,000 square feet.

The Board believes the aforementioned expansion will become a growth driver for the Group's businesses, further consolidate the Group's position in the industry as a one-stop comprehensive healthcare and medical service provider, and effectively expand its healthcare and medical market share.

For April to June 2021, the Group expects to record:

(i) overall Sales Volume of no less than HK$720 million for the Quarter, representing an increase of no less than 52% as compared with the same period last year and an increase of no less than 35% as compared with the same period in 2019;

(ii) an increase in Sales Volume in those clinics and service centers located in Mainland China of no less than 36% for the Quarter as compared with the same period last year and an increase of no less than 91% as compared with the same period in 2019; and

(iii) an increase in Sales Volume of medical services offered by the Group of no less than 104% for the Quarter as compared with the same period last year and an increase of no less than 131% as compared with the same period in 2019.

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories and a professional hair care center HAIR FOREST.

*According to an independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Singapore cord blood bank Cryoviva establishes footprint in the UAE

Singapore, Jul 27, 2021 – (ACN Newswire) – Family cord blood bank Cryoviva Singapore is pleased to announce that it has made a successful foray into the UAE market in line with its strategic growth plans. After 7 years of serving young families in Singapore, the expansion into Dubai and the other Emirates in the UAE is an important milestone for Cryoviva.

Rajesh Nair, CEO of Cryoviva Singapore

"This is an important step in our journey, fulfilling our mission to give every family the chance to benefit from the medical potential of cord stem cells should they need it. That we have been able to attract young families in the UAE to trust us with their baby's precious cord blood is not only a testament to our credentials as a company, but also to Singapore's reputation for world-class facilities and strict adherence to high-quality standards. We invite healthcare providers offering maternity services to collaborate with us to provide even greater service to their valued patients," said Rajesh Nair, CEO of Cryoviva Singapore.

"While we continue with our growth efforts in several other countries – both in the ASEAN region as well as in the Middle East, I would also like to reiterate our commitment to serving families in Singapore. We believe that there is still considerable potential for family cord blood banking services to grow in a developed and discerning market like Singapore. We also look forward to contributing to further our city's position as a great destination to avail of world-class healthcare services."

About Cryoviva Singapore

Established in 2014, Cryoviva (https://cryoviva.com.sg) is a well-regarded family cord blood bank in Singapore. The company is part of an international group backed by multinational investors. The Cryoviva group has successfully stored over 160,000 cord blood units. Cryoviva's cord blood storage facility in Singapore is MoH-licensed, AABB accredited and IS ISO 9001:2015 QMS Certified, testaments to the stringent processes and quality standards that it adheres to. With its central location and proximity to most major maternity hospitals in Singapore, cord blood samples reach our facilities quickly and efficiently to ensure top quality maintenance upon storage.

Media Contact:
Krish Sharma, General Manager
Cryoviva Singapore,
Tel: +65-9651 7080
E-mail: krish@cryoviva.com.sg

Copyright 2021 ACN Newswire. All rights reserved. http://www.acnnewswire.com